Molecular Subtype-Specific Mechanisms and Therapeutic Strategies in Sepsis

Recruiting now

Conditions studied: Sepsis, Septic Shock

In brief

Sepsis is a complex syndrome that causes lethal organ dysfunction due to an abnormal host response to infection. No drug specifically targeting sepsis has been approved. The heterogeneity in sepsis pathophysiology hinders the identification of patients who would benefit, or be harmed, from specific therapeutic interventions. Recent clinical genomics studies have shown that sepsis patients can be stratified as molecular subtypes, or subclasses, with clinical implications. Classifying sepsis patients as molecular subtypes revealed that a poor prognosis subtype was characterized by immunosuppression and septic shock. Therefore, it has become essential to identify patients who may benefit from or be adversely affected by specific treatments, thereby identifying bona fide treatable traits or endotypes. The goal of this study is to assist the physician at the bedside in tailoring the treatment of an individual patient suffering from sepsis by generating rapid molecular information about immune status.

Key facts

Study ID

NCT06287684

Run by

Mater Dei Hospital, Malta

People needed

460

Starts

2023-09-13

Expected to finish

2028-12-30

Last updated by the study team

2025-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age ≥ 18 years
• Consent card signed

You may not qualify if…

• Consent card not signed
• Pregnancy
• Prisoners
• Elective cardiac surgery patients with an uncomplicated stay.

Where it is running

• Mater Dei hospital, Intensive Therapy Unit — Msida, Malta (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.